Molecular structure of Atorvastatin Lactone, CAS Number: 125995-03-1
Atorvastatin Lactone (CAS 125995-03-1)
See product citations (3)
Application:
Atorvastatin Lactone is an atorvastatin intermediate inhibitor of MAP and HMG-CoA
CAS Number:
125995-03-1
Purity:
≥95%
Molecular Weight:
540.62
Molecular Formula:
C33H33FN2O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Atorvastatin Lactone is a metabolite of Atorvastin acid (sc-337542), which is an inhibitor of HMG-CoA reductase. By affecting Atorvastatin acid action, Atorvastatin Lactone prevents inhibition of P-glycoprotein mediated Rhodamine 123 (sc-208306) transport in cells. Studies suggest that Atorvastatin is also a potent scavenger for free radicals and prevents toxic effects of Gentamycin (sc-357362) by inhibiting NF-κB and MAPK signaling pathways.
Atorvastatin Lactone (CAS 125995-03-1) References
- HMG-CoA reductase inhibitors and P-glycoprotein modulation. | Bogman, K., et al. 2001. Br J Pharmacol. 132: 1183-92. PMID: 11250868
- Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways. | Ozbek, E., et al. 2009. Ren Fail. 31: 382-92. PMID: 19839839
- Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. | Narwal, R., et al. 2010. Clin Pharmacokinet. 49: 693-702. PMID: 20818835
- Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis. | Riedmaier, S., et al. 2011. Front Pharmacol. 2: 41. PMID: 21852972
- Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. | Dostalek, M., et al. 2012. Clin Pharmacokinet. 51: 591-606. PMID: 22775412
- UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. | Stormo, C., et al. 2013. Mol Diagn Ther. 17: 233-7. PMID: 23580084
- Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial. | Kristiansen, O., et al. 2021. Eur Heart J Cardiovasc Pharmacother. 7: 507-516. PMID: 32609361
- Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines. | Hoste, E., et al. 2023. Ther Drug Monit. 45: 400-408. PMID: 36253893
- Effect of polymorphisms in drug metabolism and transportation on plasma concentration of atorvastatin and its metabolites in patients with chronic kidney disease. | Jiang, Z., et al. 2023. Front Pharmacol. 14: 1102810. PMID: 36923356
- PBPK Modeling of Azithromycin Systemic Exposure in a Roux-en-Y Gastric Bypass Surgery Patient Population. | Avvari, SK., et al. 2023. Pharmaceutics. 15: PMID: 38004500
- SLCO1B1 Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia. | Wagner, JB., et al. 2024. Genes (Basel). 15: PMID: 38254988
- Impact of CYP2C19 Gene Variants on Long-Term Treatment with Atorvastatin in Patients with Acute Coronary Syndromes. | Čereškevičius, D., et al. 2024. Int J Mol Sci. 25: PMID: 38791422
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Atorvastatin Lactone, 10 mg | sc-207307A | 10 mg | $240.00 | |||
Atorvastatin Lactone, 25 mg | sc-207307 | 25 mg | $292.00 | |||
Atorvastatin Lactone, 50 mg | sc-207307B | 50 mg | $490.00 | |||
Atorvastatin Lactone, 100 mg | sc-207307C | 100 mg | $978.00 | |||
Atorvastatin Lactone, 250 mg | sc-207307D | 250 mg | $1997.00 |